Popular Articles
Stretch Mark

PolyMedix Receives Regulatory Clearance To Initiate Second Phase I Clinical Study Of Novel Systemic Antibiotic Compound
PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has received a notice of no objection from Health Canada for the Company"s Clinical Trial Application ("CTA") for its defensin mimetic antibiotic compound, PMX-30063. This notice of no objection allows for the initiation of the second human clinical study in Canada. PMX-30063 is a defensin mimetic antibiotic compound, the first of an entirely new class of antibiotic drugs that is believed to work in such a way that makes bacterial resistance unlikely to develop.
generic viagra online
Informa Healthcare Journals To Unite On One Platform - Pharmaceutical Science And Medicine Journals Create Robust Information Service For Customers
Informa Healthcare - one of the world"s leading medical and scientific publishers- has announced that its peer-reviewed medical titles will be joining the company"s pharmaceutical science titles to form one, united platform for drug discovery and clinical medicine on http://www.Informahealthcare.com.
News of the day
CDC Reports 21,449 Cases Of Swine Flu, Including 87 Deaths In The USA
The Centers for Disease Control and Prevention (CDC), USA, in its latest update, dated Friday evening, 19th June, 2009, reports a total of 21,449 confirmed human cases of swine flu A(H1N1) infection, including 87 deaths. Authorities say the novel A(H1N1) influenza virus has not mutated and is not more virulent (aggressive) than most normal seasonal human flu viruses. However, health services are bracing themselves for a busy flu season this winter as the swine flu virus will have been circulating for several months, but will still be a relatively novel one.
Health Insurance

Hospital Pharmacists Launch Pioneering Healthy Lifestyle Scheme, UK

Inpatients at Southampton"s teaching hospitals are to be offered advice on lifestyle and weight management as part of a radical new project. Southampton University Hospitals NHS Trust"s pharmacy team has invented an innovative plan to tackle obesity during routine risk assessments for venous thromboembolism (VTE), better known as blood clots. All patients admitted to hospital are susceptible to VTE, which causes an estimated 25,000 preventable deaths per year in England, so safety reviews are now carried out on all inpatients. Pharmacists conduct these assessments and identify risk factors, such as obesity, that can cause fatal clots. SUHT is now developing a pilot project in collaboration with primary care services to expand the role of pharmacists, allowing them to advise patients about lifestyle and obesity management as opposed to just recording them as a VTE risk. Pharmacists will supply appropriate patients with information leaflets about the help available in the community as well as contacting their GP. If a patient shows interest in improving their health immediately, the pharmacist will offer direct consultation to set them targets and decide on the most appropriate way forward. Sharron Millen, head of clinical pharmacy at SUHT, said: "We are currently finalising plans to pilot this in the surgical pre-assessment clinic, where we believe active intervention might prevent complications during and after surgery. "Within the clinic, pharmacists will conduct VTE risk assessments for each patient, which allows them to identify those who might benefit from lifestyle support, i.e. help to lose weight, stop smoking." She added: "We hope that by supporting patients who have unhealthy lifestyles and are at high risk of VTE, we can add quality to their care and, in the longer term, reduce their risk of thrombosis and other long-term conditions." Southampton University Hospitals NHS Trust


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):